Company intelligence / Profile preview

Combioxin SA

Epalinges, VD, Switzerlandcombioxin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Combioxin’s lead asset, CAL02, is a novel first-in-class anti-toxin agent using engineered liposomes to neutralize bacterial virulence factors. It is being developed for severe community-acquired bacterial pneumonia and has received FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations. A global Phase 2 clinical study is underway. Early clinical results published in The Lancet Infectious Diseases described the approach as a “medical breakthrough.” In August 2021, Eagle Pharmaceuticals obtained worldwide commercial rights to CAL02.

Therapeutic areas: Infectious Diseases
Modalities: Liposome-based anti-toxin agents
Industry: Biotech

Drug pipeline

1 asset

CAL02

Phase 2

Indications: Severe community-acquired bacterial pneumonia

Partnerships

Eagle Pharmaceuticals Inc.

Beyond the preview

Go deeper on Combioxin SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combioxin SA.

Explore the full profile